GH Research Announces Two-Peer Reviewed Publications From Its Phase 2B Clinical Program Of GH001 For Treatment-Resistant Depression

GH Research PLC (NASDAQ: GHRS) announced two peer-reviewed publications from its Phase 2b clinical program for GH001, targeting treatment-resistant depression (TRD). The publications include primary trial results in JAMA Psychiatry and an analysis in Psychopharmacology Bulletin, showing that GH001's efficacy remains consistent regardless of prior treatment failures. Notably, remission rates at Day 8 ranged from 53.9% to 63.6% for patients with 2 to 5+ prior failures, and at Month 6, rates ranged from 61.5% to 85.7%, indicating no decline with higher treatment histories.